Status:
UNKNOWN
The Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborating Sponsors:
Merck Frosst Canada Ltd.
Conditions:
Osteoporosis
Eligibility:
All Genders
55+ years
Phase:
PHASE3
Brief Summary
To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture
Eligibility Criteria
Inclusion
- Male and Female aged \> 55 Low trauma hip fracture up to 90 days Be willing to submit to periodic bone mineral density radiographic studies of the spine \& 24 hr urine collection Written informed consent
- \-
Exclusion
- Disorders known to affect bone metabolism Not taking bisphosphonates within last 6 months Drugs known to interfere with calcium metabolism within the lats 6 months prior to hip fracture serum calcium\> 2.65 mmol/L Treatment with any investigational drug within the last 30 days
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2007
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00346190
Start Date
January 1 2003
End Date
April 1 2007
Last Update
April 12 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mcgill University Health center
Montreal, Quebec, Canada, H3A 1A1